Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05170061 · ClinicalTrials.gov registry record · Phase 3
24 Hour Ambulatory Cardiac Oxygen Consumption
A Phase 3 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
NCT05170061 is a Phase 3 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 26 participants.
The verdict
NCT05170061, a Phase 3 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
Study Summary
A randomized,double-blind, active controlled,15 week study to evaluate the effects of nebivolol and valsartan alone and in combination on 24-hour ambulatory cardiac work and variability of heart rate-mean central systolic pressure product.
Interventions
- DRUG Nebivolol
- DRUG Valsartan
- DRUG Nebivolol/valsartan combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05170061
The ClinicalTrials.gov registry entry for NCT05170061 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nebivolol is the first listed.
NCT05170061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05170061 about?
NCT05170061 is a clinical study titled "24 Hour Ambulatory Cardiac Oxygen Consumption". A randomized,double-blind, active controlled,15 week study to evaluate the effects of nebivolol and valsartan alone and in combination on 24-hour ambulatory cardiac work and variability of heart rate-mean central systolic pressure product.
What is the current status of trial NCT05170061?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2013-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT05170061?
The interventions under investigation include: Nebivolol (DRUG), Valsartan (DRUG), Nebivolol/valsartan combination (DRUG).
Who is sponsoring clinical trial NCT05170061?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.